{
    "clinical_study": {
        "@rank": "73723", 
        "arm_group": [
            {
                "arm_group_label": "ASP0456 lowest dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP0456 low dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP0456 middle dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP0456 high dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "placebo group", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to investigate the efficacy, safety, and plasma concentration change of\n      ASP0456 in patients with constipation-predominant irritable bowel syndrome."
        }, 
        "brief_title": "A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Constipation-predominant Irritable Bowel Syndrome (IBS-C)", 
        "condition_browse": {
            "mesh_term": [
                "Constipation", 
                "Irritable Bowel Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a multicenter, double-blind, placebo-controlled, parallel-group, comparative\n      study to investigate dose-responses of efficacy, safety, and pharmacokinetics of ASP0456 in\n      patients with constipation-predominant irritable bowel syndrome (IBS-C) according to the\n      Rome III Diagnostic Criteria (2006 revised edition, established by the Rome III Committee)\n      after oral administration of ASP0456."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who had abdominal pain or discomfort repeatedly for at least 3 days per\n             month during the 3 months before screening examination associated with at least 2 out\n             of the following 3 conditions: (1) Improvement with defecation; (2) Onset associated\n             with a change in frequency of stool; and (3) Onset associated with a change in form\n             (appearance) of stool, and had the above symptom (IBS symptom) 6 months or more\n             before the screening examination period.\n\n          -  Patients with \u226525% of stools hard or lumpy (with each bowel movement occurring\n             without antidiarrheal, laxative, suppository or enema) and <25% of them loose (mushy)\n             or watery during the 3 months before the screening examination.\n\n          -  Patients who had pancolonoscopy or contrast enema (or sigmoidoscopy) after the onset\n             of IBS symptom and had no organic changes.\n\n        Exclusion Criteria:\n\n          -  Patients with a history of surgical resection of the stomach, gallbladder, small\n             intestine or large intestine\n\n          -  Patients with other concurrent diseases that may affect the digestive tract passage\n             or large intestinal function\n\n          -  Patients with other concurrent diseases that may affect the assessment of abdominal\n             pain/discomfort\n\n          -  Patients with blood pressure, pulse rate, clinical laboratory test, or 12-lead ECG at\n             the time of screening examination that was rated as Grade 2 or greater on the\n             \"Severity Criteria for Drug Adverse Reaction\" and judged to be clinically significant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "559", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714843", 
            "org_study_id": "0456-CL-0021"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ASP0456 lowest dose group", 
                    "ASP0456 low dose group", 
                    "ASP0456 middle dose group", 
                    "ASP0456 high dose group"
                ], 
                "description": "oral", 
                "intervention_name": "ASP0456", 
                "intervention_type": "Drug", 
                "other_name": "linaclotide"
            }, 
            {
                "arm_group_label": "placebo group", 
                "description": "oral", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ASP0456", 
            "constipation", 
            "irritable bowel syndrome (IBS)", 
            "linaclotide"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyusyu", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "5", 
        "official_title": "Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Constipation-predominant Irritable Bowel Syndrome", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Global assessment of relief of IBS symptoms Responder", 
            "safety_issue": "No", 
            "time_frame": "Weekly for 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714843"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "SBM (Spontaneous Bowel Movement) Responder", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "CSBM (Complete SBM) Responder", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "Abnormal bowel habits improvement Responder", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "Abdominal pain/discomfort relief Responder", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "Changes in weekly average of SBM frequency", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "Changes in weekly average of CSBM frequency", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "Changes in weekly average of stool form scores", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "Changes in weekly average of abdominal pain/discomfort severity", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "Changes in weekly average of straining severity", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "Changes in IBS-QOL-J scores (entire scores or scores on the sub-scales)", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 12 weeks"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, clinical laboratory tests and 12-lead ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "for 12 weeks"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}